Business & Economy ยท South Africa
Aspen Pharmacare to Sell Women's Health Product in Europe to Ennogen
South African drugmaker Aspen Pharmacare is to sell a women's health product in Europe to Ennogen. The available information does not name the product, give the price or terms, the markets covered, or say when the deal is expected to close, so this account is limited to the announced sale.
South Africa's Aspen Pharmacare is to sell a women's health product in Europe to Ennogen, according to the available information.
The arrangement involves the transfer of the product's European business to the buyer. The material supplied does not name the product, the specific European markets covered or the therapeutic area beyond its description as a women's health product.
Financial terms were not disclosed in the information available. There is no detail on the sale price, any milestone or royalty payments, or the expected timetable for completion. It is also unclear whether regulatory approvals or other conditions apply to the transaction.
The information does not include comment from either company, nor does it explain Aspen's reasons for the sale or how it fits into the company's wider portfolio or strategy. No details are given on the effect on staff, manufacturing or supply arrangements.
Aspen Pharmacare is a South African pharmaceutical company. Further announcements from the companies would be needed to establish the scale and significance of the deal. This account is limited to the reported sale itself and will need updating if more details emerge.